To analyze the effect of sacubitril valsartan sodium tablets combined with metoprolol sustained-release tablets in the treatment of chronic heart failure (CHF).

A total of 132 patients with CHF treated in Puyang People’s Hospital from April 2020 to March 2022 were selected, and the patients were divided into the study group and the control group by random number table method, with 66 cases in each group. The control group was treated with metoprolol sustained-release tablets. The study group was treated with sacubitril valsartan sodium tablets based on the treatment of the control group. The efficacy, incidence of adverse reactions, cardiac function indexes including left ventricular fractional shortening (FS), left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVDs), serum factors including N-terminal pro-B-type natriuretic peptide (NT-proBNP) and C-reactive protein (CRP), and Minnesota heart failure quality of life questionnaire (MLHFQ) scores before and after treatment were compared between the two groups.

The total effective rate of the study group was 96.97% (64/66), which was higher than that of the control group (75.76%, 50/66), P<0.05. Compared with the control group, the levels of FS and LVEF in the study group were higher, and the level of LVDs was lower after treatment (P<0.05), the levels of NT-proBNP and CRP in the study group were lower (P<0.05), the MLHFQ score of the study group was lower than that of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the study group (6.06%, 4/66) and the control group (10.61%, 7/66), P>0.05.

Sacubitril valsartan sodium tablets combined with metoprolol sustained-release tablets in the treatment of CHF can alleviate body inflammation, improve cardiac function and quality of life. And combination of them has significant therapeutic effects and good safety.

Heart failure; Sacubitril valsartan sodium tablets; Metoprolol sustained-release tablets